Udaya B. S. Prakash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Udaya B. S. Prakash has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Anthony W. Stanson
1 shared publicationEdgar Betancourt
Division of Anatomic Pathology (E.B.), Mayo Clinic, Rochester, Minn
1 shared publicationJason M. Golbin
Pulmonary and Critical Care, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication- Karen L. Swanson
Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN
1 shared publication Marek A. Martynowicz
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Medical School and Mayo Medical Center, Rochester, MN 55905-0001, USA
1 shared publicationRicardo E. Blanco
1 shared publication
Latest Publications
- 28 December 2012
- Published by Springer Nature
- p. 471-480
Bronchoscopy and Interventional Pulmonology: Reflections on the Past, the Present, and the Future
- 28 December 2012
- Published by Springer Nature
- p. 471-480
Bronchoscopy and Interventional Pulmonology: Reflections on the Past, the Present, and the Future
- Open Access
- 9 August 2006
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 28 (6) , 1081-1084
Is bronchoscopic lung biopsy helpful in the management of patients with diffuse lung disease?
Few studies have evaluated how the results of bronchoscopic lung biopsy (BLB) affect clinical management. The objective of the present study was to evaluate the clinical usefulness of BLB in the overall management of patients with diffuse pulmonary diseases.The study was a retrospective analysis of patients who underwent fluoroscopy-guided BLB over a 2-yr period. Patients whose biopsy was of a lung mass or single dominant lung nodule were excluded. The usefulness of BLB was assessed to determine whether the results affected the clinical management of these patients.During the study period, 603 patients underwent 651 BLB procedures. The results of BLB were clinically helpful in 494 (75.9%) out of 651 procedures. No diagnostic abnormality was identified in 107 (16.4%) out of the 651 biopsy procedures. This finding was clinically helpful in 59 (55.1%) out of 107 procedures, as the results excluded specific processes suspected before BLB. In 52 procedures (8% of all BLB), no lung parenchyma was obtained.In conclusion, bronchoscopic lung biopsy is a clinically useful test in ∼75% of procedures. In the 25% of bronchoscopic lung biopsies that were clinically unhelpful, the reason for failure in approximately one-third of patients was the failure of the procedure to obtain an adequate quantity of lung parenchyma for a meaningful histological analysis.
- 9 August 2006
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 28 (6) , 1081-1084
Open AccessIs bronchoscopic lung biopsy helpful in the management of patients with diffuse lung disease?
Few studies have evaluated how the results of bronchoscopic lung biopsy (BLB) affect clinical management. The objective of the present study was to evaluate the clinical usefulness of BLB in the overall management of patients with diffuse pulmonary diseases.The study was a retrospective analysis of patients who underwent fluoroscopy-guided BLB over a 2-yr period. Patients whose biopsy was of a lung mass or single dominant lung nodule were excluded. The usefulness of BLB was assessed to determine whether the results affected the clinical management of these patients.During the study period, 603 patients underwent 651 BLB procedures. The results of BLB were clinically helpful in 494 (75.9%) out of 651 procedures. No diagnostic abnormality was identified in 107 (16.4%) out of the 651 biopsy procedures. This finding was clinically helpful in 59 (55.1%) out of 107 procedures, as the results excluded specific processes suspected before BLB. In 52 procedures (8% of all BLB), no lung parenchyma was obtained.In conclusion, bronchoscopic lung biopsy is a clinically useful test in ∼75% of procedures. In the 25% of bronchoscopic lung biopsies that were clinically unhelpful, the reason for failure in approximately one-third of patients was the failure of the procedure to obtain an adequate quantity of lung parenchyma for a meaningful histological analysis.
- 1 October 2005
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 26 (05) , 527-540
Lungs in Hemoglobinopathies, Erythrocyte Disorders, and Hemorrhagic Diatheses
The erythropoietic system plays a major role in tissue oxygenation because the erythrocytes are the primary carriers of oxygen in the form of oxyhemoglobin. Therefore, clinical entities such as abnormal hemoglobins, polycythemia, anemia, and significant changes in blood volume frequently produce alterations in various respiratory functions. The pulmonary manifestations can vary from mild respiratory illness to life-threatening emergencies with high mortality rates. Among the hemoglobinopathies, sickle cell disease is clinically the most important and commonly associated with serious pulmonary consequences, including acute chest syndrome, pneumonia, infarction due to in situ thrombosis, bone marrow fat embolism of pulmonary vasculature, bone marrow infarction, pulmonary hypertension, and other abnormalities. Hemoglobinopathies with high and low affinity for oxygen and other abnormal hemoglobinopathies occasionally cause clinically significant respiratory complications by interfering with normal tissue oxygenation. Acquired methemoglobinemia can cause alarming cyanosis and medical emergency. Erythrocyte disorders are associated with pulmonary complications, including pulmonary hypertension, alveolar fibrosis, and pulmonary dysfunction. Coagulation disorders, both the inherited and acquired types, have the potential to affect the respiratory system in the form of hemorrhage from the airways, lung parenchyma, or pulmonary hypertension. The following paragraphs describe the common pulmonary complications and manifestations associated with hemoglobinopathies, erythrocyte disorders, and coagulation abnormalities.
- 1 October 2005
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 26 (05) , 527-540
Lungs in Hemoglobinopathies, Erythrocyte Disorders, and Hemorrhagic Diatheses
The erythropoietic system plays a major role in tissue oxygenation because the erythrocytes are the primary carriers of oxygen in the form of oxyhemoglobin. Therefore, clinical entities such as abnormal hemoglobins, polycythemia, anemia, and significant changes in blood volume frequently produce alterations in various respiratory functions. The pulmonary manifestations can vary from mild respiratory illness to life-threatening emergencies with high mortality rates. Among the hemoglobinopathies, sickle cell disease is clinically the most important and commonly associated with serious pulmonary consequences, including acute chest syndrome, pneumonia, infarction due to in situ thrombosis, bone marrow fat embolism of pulmonary vasculature, bone marrow infarction, pulmonary hypertension, and other abnormalities. Hemoglobinopathies with high and low affinity for oxygen and other abnormal hemoglobinopathies occasionally cause clinically significant respiratory complications by interfering with normal tissue oxygenation. Acquired methemoglobinemia can cause alarming cyanosis and medical emergency. Erythrocyte disorders are associated with pulmonary complications, including pulmonary hypertension, alveolar fibrosis, and pulmonary dysfunction. Coagulation disorders, both the inherited and acquired types, have the potential to affect the respiratory system in the form of hemorrhage from the airways, lung parenchyma, or pulmonary hypertension. The following paragraphs describe the common pulmonary complications and manifestations associated with hemoglobinopathies, erythrocyte disorders, and coagulation abnormalities.
- 24 April 2002
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 23 (2) , 103-114
Pulmonary Alveolar Microlithiasis
Pulmonary alveolar microlithiasis is a rare pulmonary disorder of unknown etiology characterized by intra-alveolar development and deposition of microliths or calcispherytes consisting of calcium phosphate. Approximately 400 cases of this rare disorder have been described in the literature. The age range of patients is from newborn to 80 years, with a mean age at diagnosis of about 35 years. No sexual predominance has been noted. In about half of the reported cases, a familial pattern has been found, with the disease usually affecting the siblings. The progression of the disease is generally very slow, some patients having been followed up for more than 30 years without evidence of change. Pulmonary function studies demonstrate a tendency toward a restrictive pattern. Chest roentgenography, high-resolution computed tomographic chest scan, and technetium-99m lung scan are useful in the diagnosis. A definitive diagnosis can be established by bronchoalveolar lavage or lung biopsy. There is no known therapy for this unusual disorder. In patients who develop progressive respiratory insufficiency and cor pulmonale, lung transplantations have been performed.
- 24 April 2002
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 23 (2) , 103-114
Pulmonary Alveolar Microlithiasis
Pulmonary alveolar microlithiasis is a rare pulmonary disorder of unknown etiology characterized by intra-alveolar development and deposition of microliths or calcispherytes consisting of calcium phosphate. Approximately 400 cases of this rare disorder have been described in the literature. The age range of patients is from newborn to 80 years, with a mean age at diagnosis of about 35 years. No sexual predominance has been noted. In about half of the reported cases, a familial pattern has been found, with the disease usually affecting the siblings. The progression of the disease is generally very slow, some patients having been followed up for more than 30 years without evidence of change. Pulmonary function studies demonstrate a tendency toward a restrictive pattern. Chest roentgenography, high-resolution computed tomographic chest scan, and technetium-99m lung scan are useful in the diagnosis. A definitive diagnosis can be established by bronchoalveolar lavage or lung biopsy. There is no known therapy for this unusual disorder. In patients who develop progressive respiratory insufficiency and cor pulmonale, lung transplantations have been performed.
- 24 April 2002
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 23 (2) , 167-176
Tracheobronchopathia Osteochondroplastica
Tracheobronchopathia osteochondroplastica (TPO) is an uncommon benign disease of unknown etiology characterized by multiple cartilaginous or bony submucosal nodules, which project into the tracheobronchial lumen. The nodules originate in the airway cartilages and thus typically spare the posterior membranous wall of the airways. The disorder is more common in men and the diagnosis is usually made in the fourth through sixth decades of life. There is no relationship to smoking or other systemic disorders. The disease is manifested by chronic cough and wheezing, which frequently lead to the mistaken diagnosis of asthma. Other pulmonary symptoms include dyspnea and hemoptysis. One of the complications is the increased incidence of recurrent respiratory infections. The pulmonary symptoms and complications are the consequence of narrowing and thickening of the airway walls. Even though roentgenologic imaging studies may indicate the diagnosis, bronchoscopy is the most definitive diagnostic test. The bronchoscopic appearance alone is diagnostic of the disease, and biopsy of the airway lesions is seldom, if ever, required. Although there is no specific therapy for this disorder, management of tracheobronchopathia osteochondroplastica includes bronchodilators, prompt treatment of pulmonary infections, and bronchoscopic dilatation when indicated.
- 24 April 2002
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 23 (2) , 167-176
Tracheobronchopathia Osteochondroplastica
Tracheobronchopathia osteochondroplastica (TPO) is an uncommon benign disease of unknown etiology characterized by multiple cartilaginous or bony submucosal nodules, which project into the tracheobronchial lumen. The nodules originate in the airway cartilages and thus typically spare the posterior membranous wall of the airways. The disorder is more common in men and the diagnosis is usually made in the fourth through sixth decades of life. There is no relationship to smoking or other systemic disorders. The disease is manifested by chronic cough and wheezing, which frequently lead to the mistaken diagnosis of asthma. Other pulmonary symptoms include dyspnea and hemoptysis. One of the complications is the increased incidence of recurrent respiratory infections. The pulmonary symptoms and complications are the consequence of narrowing and thickening of the airway walls. Even though roentgenologic imaging studies may indicate the diagnosis, bronchoscopy is the most definitive diagnostic test. The bronchoscopic appearance alone is diagnostic of the disease, and biopsy of the airway lesions is seldom, if ever, required. Although there is no specific therapy for this disorder, management of tracheobronchopathia osteochondroplastica includes bronchodilators, prompt treatment of pulmonary infections, and bronchoscopic dilatation when indicated.
- 24 April 2002
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 23 (2) , 083-084
Rare or Orphan Lung Diseases
It is an honor for me to edit this issue of the Seminars in Respiratory and Critical Care Medicine on unusual and rare respiratory disorders. At the very outset, it is important to recognize that there are many more unusual or rare lung diseases than discussed in this issue of the Seminars. The disorders selected for discussion here are indeed unusual and rare, but they are important enough to warrant the cognizance of practicing pulmonologists and interested physicians. Some of the disorders, such as tracheopathia osteoplastica and pulmonary alveolar microlithiasis, are perhaps more common than we recognize. They remain undetected, given the lack of symptoms. Lymphangioleiomyomatosis (LAM) is a perplexing disorder; Johnson and Tattersfield provide detailed information on the clinical aspects of this disease. Their discussion also includes the current information on the biology of the LAM cells and the role of the receptors for estrogen and progesterone in their nuclei. Because LAM possesses histologic features identical to those in tuberous sclerosis, the relationship of LAM to tuberous sclerosis is also discussed. Pulmonary Langerhans' cell histiocytosis (PLCH) is, as noted by the authors Vassallo and Limper, an uncommonly important cause of interstitial lung disease. PLCH is an important diagnostic consideration in the differential diagnosis of diffuse infiltrative lung disease, particularly amongst smokers. The authors describe the clinical details as well as review the recent progress in our understanding of the etiology, clinical presentation, and diagnostic and therapeutic approaches to PLCH. The authors also summarize a rational diagnostic algorithm and current management strategies. Pulmonary alveolar microlithiasis is included in this issue of the Seminars because of its rarity. It is an extremely uncommon lung disease described in approximately 400 patients worldwide. Of all the rare and uncommon disorders covered in this issue of the Seminars, microlithiasis has shown a strong tendency to occur among family members. Beyond this documented fact, the etiology remains unknown. The disorder possesses enough clinical and diagnostic characteristics that it should be relatively easy to establish the diagnosis. In their manuscript on pulmonary alveolar proteinosis, Mazzone, Thomassen, and Kavuru pay special attention to the newer developments in the understanding of this uncommon pulmonary disease. The encouraging aspect of dealing with this disorder is that many investigators are currently actively carrying out animal as well as clinical research to learn the pathogenetic mechanism of this disease. Mazzone and colleagues discuss the relatively newly gathered information on the role played by granulocyte-macrophage colony-stimulating factor (GM-CSF) gene in the development of pulmonary alveolar proteinosis. The idea that the disorder is the result of relative GM-CSF deficiency has led to therapeutic trials in which GM-CSF has been administered subcutaneously and by aerosolization. Allen, Magro, and King provide an excellent outline of the confusing entities frequently lumped together under the broad category of eosinophilic pneumonias, or ``PIE'' syndromes or pulmonary infiltrates with peripheral blood eosinophilia. The discussion encompasses the differences between acute and chronic eosinophilic pneumonia, differential diagnoses of these two major types of eosinophilic pneumonias, and diagnostic features and tests, as well as therapy. The article by Parish and Rosenow includes a comprehensive discussion of mediastinal granuloma. This disorder is distinctly more common in the United States than in other regions of the world. Many terms have been used synonymously to describe mediastinal granuloma, including mediastinal fibrosis, sclerosing mediastinitis, mediastinal adenitis, mediastinal collagenosis, and fibrosing mediastinitis. This entity leads to chronic, nonmalignant, but often progressive, inflammatory disease of the mediastinum. Currently, the cause of this unusual disorder is thought to stem from the antigenic stimulation of fibroblasts by histoplasma infection, even though tuberculosis can lead to similar problems. The systemic as well as respiratory aspects of relapsing polychondritis are well outlined by Staats, Utz, and Michet Jr. Relapsing polychondritis is an unusual clinical entity that is frequently discussed with other collagen and rheumatologic disorders because of its systemic manifestations and clinical features. Although it is well known that relapsing polychondritis is primarily a disease of cartilage, it is one of the more difficult diseases in terms of our ability to clearly document the diagnosis. According to the authors, there have been over 600 cases reported in the literature. Respiratory complications are important because they can lead to life-threatening situations. The difficult clinical problem of pulmonary and tracheobronchial amyloidosis is well outlined by Berk, O'Regan, and Skinner. Whereas pulmonary amyloidosis may present with symptoms caused by parenchymal involvement, the tracheobronchial variety usually presents with symptoms similar to those caused by a variety of airway disorders. It is not typically associated with systemic amyloidosis or pulmonary parenchymal involvement. It is a rare manifestation of amyloidosis, usually presenting with common symptoms that mimic many respiratory processes. Tracheobronchial amyloidosis is often recurrent, and requires repeated attempts at resection to minimize patient symptoms and potential complications from further airway destruction. Another rare disorder discussed here is tracheobronchopathia osteochondroplastica. In my opinion, this uncommon disorder of the major airways with a lengthy descriptive designation may not be as uncommon as is reported. Many...
- 24 April 2002
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 23 (2) , 083-084
Rare or Orphan Lung Diseases
It is an honor for me to edit this issue of the Seminars in Respiratory and Critical Care Medicine on unusual and rare respiratory disorders. At the very outset, it is important to recognize that there are many more unusual or rare lung diseases than discussed in this issue of the Seminars. The disorders selected for discussion here are indeed unusual and rare, but they are important enough to warrant the cognizance of practicing pulmonologists and interested physicians. Some of the disorders, such as tracheopathia osteoplastica and pulmonary alveolar microlithiasis, are perhaps more common than we recognize. They remain undetected, given the lack of symptoms. Lymphangioleiomyomatosis (LAM) is a perplexing disorder; Johnson and Tattersfield provide detailed information on the clinical aspects of this disease. Their discussion also includes the current information on the biology of the LAM cells and the role of the receptors for estrogen and progesterone in their nuclei. Because LAM possesses histologic features identical to those in tuberous sclerosis, the relationship of LAM to tuberous sclerosis is also discussed. Pulmonary Langerhans' cell histiocytosis (PLCH) is, as noted by the authors Vassallo and Limper, an uncommonly important cause of interstitial lung disease. PLCH is an important diagnostic consideration in the differential diagnosis of diffuse infiltrative lung disease, particularly amongst smokers. The authors describe the clinical details as well as review the recent progress in our understanding of the etiology, clinical presentation, and diagnostic and therapeutic approaches to PLCH. The authors also summarize a rational diagnostic algorithm and current management strategies. Pulmonary alveolar microlithiasis is included in this issue of the Seminars because of its rarity. It is an extremely uncommon lung disease described in approximately 400 patients worldwide. Of all the rare and uncommon disorders covered in this issue of the Seminars, microlithiasis has shown a strong tendency to occur among family members. Beyond this documented fact, the etiology remains unknown. The disorder possesses enough clinical and diagnostic characteristics that it should be relatively easy to establish the diagnosis. In their manuscript on pulmonary alveolar proteinosis, Mazzone, Thomassen, and Kavuru pay special attention to the newer developments in the understanding of this uncommon pulmonary disease. The encouraging aspect of dealing with this disorder is that many investigators are currently actively carrying out animal as well as clinical research to learn the pathogenetic mechanism of this disease. Mazzone and colleagues discuss the relatively newly gathered information on the role played by granulocyte-macrophage colony-stimulating factor (GM-CSF) gene in the development of pulmonary alveolar proteinosis. The idea that the disorder is the result of relative GM-CSF deficiency has led to therapeutic trials in which GM-CSF has been administered subcutaneously and by aerosolization. Allen, Magro, and King provide an excellent outline of the confusing entities frequently lumped together under the broad category of eosinophilic pneumonias, or ``PIE'' syndromes or pulmonary infiltrates with peripheral blood eosinophilia. The discussion encompasses the differences between acute and chronic eosinophilic pneumonia, differential diagnoses of these two major types of eosinophilic pneumonias, and diagnostic features and tests, as well as therapy. The article by Parish and Rosenow includes a comprehensive discussion of mediastinal granuloma. This disorder is distinctly more common in the United States than in other regions of the world. Many terms have been used synonymously to describe mediastinal granuloma, including mediastinal fibrosis, sclerosing mediastinitis, mediastinal adenitis, mediastinal collagenosis, and fibrosing mediastinitis. This entity leads to chronic, nonmalignant, but often progressive, inflammatory disease of the mediastinum. Currently, the cause of this unusual disorder is thought to stem from the antigenic stimulation of fibroblasts by histoplasma infection, even though tuberculosis can lead to similar problems. The systemic as well as respiratory aspects of relapsing polychondritis are well outlined by Staats, Utz, and Michet Jr. Relapsing polychondritis is an unusual clinical entity that is frequently discussed with other collagen and rheumatologic disorders because of its systemic manifestations and clinical features. Although it is well known that relapsing polychondritis is primarily a disease of cartilage, it is one of the more difficult diseases in terms of our ability to clearly document the diagnosis. According to the authors, there have been over 600 cases reported in the literature. Respiratory complications are important because they can lead to life-threatening situations. The difficult clinical problem of pulmonary and tracheobronchial amyloidosis is well outlined by Berk, O'Regan, and Skinner. Whereas pulmonary amyloidosis may present with symptoms caused by parenchymal involvement, the tracheobronchial variety usually presents with symptoms similar to those caused by a variety of airway disorders. It is not typically associated with systemic amyloidosis or pulmonary parenchymal involvement. It is a rare manifestation of amyloidosis, usually presenting with common symptoms that mimic many respiratory processes. Tracheobronchial amyloidosis is often recurrent, and requires repeated attempts at resection to minimize patient symptoms and potential complications from further airway destruction. Another rare disorder discussed here is tracheobronchopathia osteochondroplastica. In my opinion, this uncommon disorder of the major airways with a lengthy descriptive designation may not be as uncommon as is reported. Many...
- 1 November 2000
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 75 (11) , 1148-1152
Tracheobronchial Amyloidosis
- 1 November 2000
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 75 (11) , 1148-1152
Tracheobronchial Amyloidosis